verified SJR 2,329 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Oxford University Press

workspace_premium Q1 — Medicine (miscellaneous) lock Subscription

Oncologist

Oncologist is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 199. It has a price of 1260 €. It has an SJR impact factor of 2,329 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,329.

Oncologist focuses its scope in these topics and keywords: cancer, patients, metastatic, colorectal, treatment, weeks, cell, therapy, review, agency, ...

ISSN: 1083-7159

Publisher: Oxford University Press

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

2,329 Q1

H-index 199

Acceptance rate pie_chart

21% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

1.260 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

2,329

H-index

199

Docs (year)

333

Docs 3y

1030

Total refs

11353

Cites 3y

4644

Citable 3y

906

Cites/Doc 2y

4.15

Ref/Doc

34.09

Immediate OA

1260 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Anti-Leukemia Chemotherapy of High-Risk Myelodysplastic Syndromes

What Patients Value When Oncologists Give News of Cancer Recurrence: Commentary on Specific Moments in Audio-Recorded Conversations

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors

Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared With Nonpregnant Patients With Breast Cancer

Cancer Disparities in the Context of Medicaid Insurance: A Comparison of Survival for Acute Myeloid Leukemia and Hodgkin's Lymphoma by Medicaid Enrollment

Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications

Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya

Bone Loss and Fracture Risk Associated with Cancer Therapy

Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists

Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors

SHOW MORE ARTICLES

Appraising Adjuvant Aromatase Inhibitor Therapy

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer

Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma - Analysis Using Diagnostic Nodes

Age-Specific Nonpersistence of Endocrine Therapy in Postmenopausal Patients Diagnosed with Hormone Receptor-Positive Breast Cancer: A TEAM Study Analysis

Advance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective Study

Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification

Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis

Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions

Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials

A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer

A Pilot Randomized Controlled Trial of Brief Cognitive-Behavioral Therapy for Anxiety in Patients with Terminal Cancer

A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

FAQs

Oncologist has an SJR of 2,329 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 1260 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Oncologist is 21%.

Oncologist

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Oncologist?

What is the APC / publication cost?

What is the acceptance rate?